$CERO

SRX Global (SRXH) will acquire CERo Therapeutics, a cellular immunotherapy company, to accelerate development of CER-1236 for blood cancers. The deal combines SRX's public infrastructure with CERo's oncology platform, aiming to enhance capital access and operational resources. CER-1236 is in Phase 1 trials, with preliminary data showing no dose-limiting toxicities in recent cohorts. The transaction is subject to closing conditions and regulatory approvals.

CERo Therapeutics Holdings agreed to sell its operating subsidiary to SRX Global for $1M in stock and debt relief. The deal includes forgiveness of $8.25M in debt and SRX assuming $1.56M in liabilities. CERo aims to reduce debt and reposition the holding company.

CERO THERAPEUTICS HOLDINGS, INC. (CERO) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Item 1.01. Entry into a Material Definitive Agreement. Stock Purchase Agreement On October 6, 2026, CERo Therapeutics Holdings, Inc., a Delaware corporation (the “Company” or “Holdings”), entered into a Stock Purchase Agreement (the “Purchase Agreement”) with SRX Global Inc., a D

SRX Global Inc. (SRXH) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Exhibit 99.1 SRX Global Acquires Senior Secured Debt in CERo Therapeutics Holdings, Inc., an Innovative Cellular Immunotherapy Company with Cancer Fighting Molecule for the Treatment of Hematologic Cancers The Debt investment is expected to accelerate development of CERo’s lead t

CERO THERAPEUTICS HOLDINGS, INC. (CERO) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Item 1.01 Entry into a Material Definitive Agreement. On August 27, 2026, CERo Therapeutics Holdings, Inc., a Delaware corporation (the “Company”), completed a secured financing transaction with SRX Global Inc. (formerly known as SRx Health Solutions, Inc.) (“SRX”). In connection

CERO THERAPEUTICS HOLDINGS, INC. (CERO) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. EX-4.1 2 ea029846301ex4-1.htm SECOND AMENDED AND RESTATED NOTE (JULY 2026) Exhibit 4.1 CERTAIN INFORMATION CONTAINED IN THIS EXHIBIT, MARKED BY [***], HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE THE REGISTRANT HAS DETERMINED THAT IT IS BOTH NOT MATERIAL AND IS THE TYPE THAT THE R

CERO THERAPEUTICS HOLDINGS, INC. (CERO) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. EX-4.1 2 ea029602201ex4-1.htm AMENDED AND RESTATED NOTE (JUNE 2026) Exhibit 4.1 CERTAIN INFORMATION CONTAINED IN THIS EXHIBIT, MARKED BY [***], HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE THE REGISTRANT HAS DETERMINED THAT IT IS BOTH NOT MATERIAL AND IS THE TYPE THAT THE REGISTRA

CERo Therapeutics (OTCQB: CERO) has appointed Eric Francois, a biotechnology finance veteran with over 25 years of experience, to its Board of Directors. Francois previously served as CFO of SCYNEXIS, where he raised over $300 million, and also held senior banking positions. His expertise in capital raising, M&A, and business development is expected to significantly contribute to CERo's cellular immunotherapy programs and ongoing human clinical trials for cancer treatment.

U.S. stocks traded mostly lower this morning, with the Nasdaq Composite falling more than 1% on Thursday. Following the market opening Thursday, the Dow traded up 0.03% to 47,644.08 while the NASDAQ fell 1.13% to 23,687.37. The S&P 500 also fell, dropping, 0.63% to 6,847.40.

Trading of the Company's shares of common stock on Nasdaq will be suspended at the open of trading on October ...